Antares nets $47m from first offering since move to Nasdaq
This article was originally published in Scrip
Antares Pharma will earn $47 million in net proceeds to fund development of its Vibex disposable pressure-assisted auto injectors for rheumatoid arthritis and male testosterone deficiency drugs through an underwritten offering of 12.5 million shares of common stock closing on 9 October at $4 per share.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.